Contraception - Pipeline Review, H1 2015
Summary
Global Markets Directs, Contraception - Pipeline Review, H1 2015, provides an overview of the Contraceptions therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news and deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens RandD pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Contraception
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and RandD brief, licensing and collaboration details and other developmental activities
- The report reviews key players involved in the therapeutics development for Contraception and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Contraception pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective RandD development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Contraception
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Contraception Overview 9
Therapeutics Development 10
Pipeline Products for Contraception - Overview 10
Pipeline Products for Contraception - Comparative Analysis 11
Contraception - Therapeutics under Development by Companies 12
Contraception - Therapeutics under Investigation by Universities/Institutes 14
Contraception - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Contraception - Products under Development by Companies 19
Contraception - Products under Investigation by Universities/Institutes 21
Contraception - Companies Involved in Therapeutics Development 22
Actavis plc 22
Agile Therapeutics, Inc. 23
ANI Pharmaceuticals, Inc. 24
Antares Pharma, Inc. 25
Evofem, Inc. 26
Hydra Biosciences, Inc. 27
Intas Pharmaceuticals Ltd. 28
Ligand Pharmaceuticals, Inc. 29
Merck Co., Inc. 30
Orbis Biosciences, Inc. 31
Pantarhei Bioscience BV 32
Teva Pharmaceutical Industries Limited 33
Contraception - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
(ethinyl estradiol + levonorgestrel) - Drug Profile 44
Product Description 44
Mechanism of Action 44
RD Progress 44
(ethinylestradiol + levonorgestrel) - Drug Profile 46
Product Description 46
Mechanism of Action 46
RD Progress 46
(nestorone + estradiol) - Drug Profile 47
Product Description 47
Mechanism of Action 47
RD Progress 47
(prasterone + estradiol + progesterone) - Drug Profile 49
Product Description 49
Mechanism of Action 49
RD Progress 49
AG-200 ER - Drug Profile 51
Product Description 51
Mechanism of Action 51
RD Progress 51
AG-200 SP - Drug Profile 52
Product Description 52
Mechanism of Action 52
RD Progress 52
Amphora - Drug Profile 53
Product Description 53
Mechanism of Action 53
RD Progress 53
esterol - Drug Profile 54
Product Description 54
Mechanism of Action 54
RD Progress 54
etonogestrel - Drug Profile 56
Product Description 56
Mechanism of Action 56
RD Progress 56
EVE-106 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RD Progress 57
levonorgestrel - Drug Profile 58
Product Description 58
Mechanism of Action 58
RD Progress 58
LJ-102 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RD Progress 60
MK-8342B - Drug Profile 61
Product Description 61
Mechanism of Action 61
RD Progress 61
Monoclonal Antibody Conjugates for Contraception - Drug Profile 62
Product Description 62
Mechanism of Action 62
RD Progress 62
norethindrone - Drug Profile 63
Product Description 63
Mechanism of Action 63
RD Progress 63
S-003296 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RD Progress 64
S-0101255 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RD Progress 65
Small Molecule 1 for Fertility Control - Drug Profile 66
Product Description 66
Mechanism of Action 66
RD Progress 66
Small Molecule 2 for Fertility Control - Drug Profile 67
Product Description 67
Mechanism of Action 67
RD Progress 67
Small Molecule to Modulate Progesterone Receptor for Fertility Control - Drug Profile 68
Product Description 68
Mechanism of Action 68
RD Progress 68
Small Molecules to Block CatSper1 Ion Channel for Contraception - Drug Profile 69
Product Description 69
Mechanism of Action 69
RD Progress 69
Synthetic Peptides for Contraception - Drug Profile 70
Product Description 70
Mechanism of Action 70
RD Progress 70
tanaproget - Drug Profile 71
Product Description 71
Mechanism of Action 71
RD Progress 71
ulipristal acetate - Drug Profile 72
Product Description 72
Mechanism of Action 72
RD Progress 72
Contraception - Recent Pipeline Updates 73
Contraception - Dormant Projects 77
Contraception - Discontinued Products 79
Contraception - Product Development Milestones 80
Featured News Press Releases 80
Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora 80
Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch 80
Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study 80
Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla 81
Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion 82
Jul 04, 2014: Teva Receives CHMP Positive Opinion for Seasonique Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries 82
Jun 26, 2014: Evofem Announces the Completion of the Largest Phase III Contraceptive Clinical Trial to Date 83
Jun 20, 2014: Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion Transdermal Delivery Device 83
Jul 24, 2013: Health Decisions Completes Enrollment of Evofems 3,400-subject Global Trial of Amphora® Non-hormonal Contraceptive Gel 84
Jul 23, 2013: Enrollment Completed for Evofems 3,200-subject Global Trial of Amphora Non-hormonal Contraceptive Gel 84
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87
List Of Tables
Number of Products under Development for Contraception, H1 2015 10
Number of Products under Development for Contraception - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Contraception - Pipeline by Actavis plc, H1 2015 22
Contraception - Pipeline by Agile Therapeutics, Inc., H1 2015 23
Contraception - Pipeline by ANI Pharmaceuticals, Inc., H1 2015 24
Contraception - Pipeline by Antares Pharma, Inc., H1 2015 25
Contraception - Pipeline by Evofem, Inc., H1 2015 26
Contraception - Pipeline by Hydra Biosciences, Inc., H1 2015 27
Contraception - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 28
Contraception - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 29
Contraception - Pipeline by Merck Co., Inc., H1 2015 30
Contraception - Pipeline by Orbis Biosciences, Inc., H1 2015 31
Contraception - Pipeline by Pantarhei Bioscience BV, H1 2015 32
Contraception - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 33
Assessment by Monotherapy Products, H1 2015 34
Assessment by Combination Products, H1 2015 35
Number of Products by Stage and Target, H1 2015 37
Number of Products by Stage and Mechanism of Action, H1 2015 39
Number of Products by Stage and Route of Administration, H1 2015 41
Number of Products by Stage and Molecule Type, H1 2015 43
Contraception Therapeutics - Recent Pipeline Updates, H1 2015 73
Contraception - Dormant Projects, H1 2015 77
Contraception - Dormant Projects (Contd..1), H1 2015 78
Contraception - Discontinued Products, H1 2015 79
List Of Figures
Number of Products under Development for Contraception, H1 2015 10
Number of Products under Development for Contraception - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Products, H1 2015 17
Assessment by Monotherapy Products, H1 2015 34
Assessment by Combination Products, H1 2015 35
Number of Products by Top 10 Targets, H1 2015 36
Number of Products by Stage and Top 10 Targets, H1 2015 37
Number of Products by Top 10 Mechanism of Actions, H1 2015 38
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 39
Number of Products by Top 10 Routes of Administration, H1 2015 40
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 41
Number of Products by Top 10 Molecule Types, H1 2015 42
Number of Products by Stage and Top 10 Molecule Types, H1 2015 43
